14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
GEHC vs CHEK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GEHC Overall Winner
6-Pillar Tally: GEHC 6 – 0 CHEK
Matrix Metrics: GEHC 9 – 1 CHEK
As of Nov 20, 2026, GE HealthCare Technologies Inc. (GEHC) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GEHC carries a Unified Composite Score of 38.6/100 (SELL) at $80.64 (14.7x Forward P/E, 13.8% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. GEHC 38.6/100 SELL), GEHC captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 0.0% operating margin) and revenue trajectory (+7.2% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GEHC vs CHEK. Trailing 12-month operating profitability (GEHC 13.8% vs CHEK 0.0%) and valuation multiples (GEHC 14.7x vs CHEK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $37.0B market capitalization and 13.8% operating margin.
OpEx & R&D Reinvestment25.5% of Rev ($5.52B)
90D Engineering Disclosures0 Published
CHEK Moat ProfileCyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GEHC vs CHEK Key Questions & Quantitative Answers
As of Nov 20, 2026, GE HealthCare Technologies Inc. (GEHC) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GEHC carries a Unified Composite Score of 38.6/100 (SELL) at $80.64 (14.7x Forward P/E, 13.8% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. GEHC 38.6/100 SELL), GEHC captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 0.0% operating margin) and revenue trajectory (+7.2% vs. +0.0% YoY).
GEHC leads the Growth & Scale pillar: GEHC posts +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin), compared with CHEK at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GEHC generates $21.6B in USD-normalized revenue versus N/A for CHEK. In operating R&D and SG&A reinvestment, GEHC deploys 25.5% of Rev ($5.52B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CHEK.
GEHC screens cheaper on headline valuation multiples. GEHC trades at 14.7x Forward P/E, 17.3x Trailing P/E, 2.24x PEG, and 2.1x EV/Revenue (8.7% FCF margin), whereas CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GEHC (20.0% ROE) versus CHEK (-226.2% ROE) capital efficiency.
In options market volatility and institutional positioning, GEHC carries 58.6% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.52β · 39% Vol realized risk). By comparison, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.